Xeris Biopharma Holdings Inc’s recently made public that its Director Schmid John P. acquired Company’s shares for reported $9720.0 on Mar 14 ’24. In the deal valued at $2.16 per share,4,500 shares were bought. As a result of this transaction, Schmid John P. now holds 11,000 shares worth roughly $21010.0.
Then, SHERMAN JEFFREY W bought 5,400 shares, generating $10,098 in total proceeds. Upon buying the shares at $1.87, the Director now owns 5,400 shares.
Before that, Pieper Steven bought 28,000 shares. Xeris Biopharma Holdings Inc shares valued at $54,600 were divested by the insider at a price of $1.95 per share. As a result of the transaction, Pieper Steven now holds 1,176,912 shares, worth roughly $2.25 million.
Oppenheimer initiated its Xeris Biopharma Holdings Inc [XERS] rating to an Outperform in a research note published on March 28, 2024; the price target was $5. A number of analysts have revised their coverage, including Craig Hallum’s analysts, who began to cover the stock in late August with a ‘”a Buy”‘ rating. Jefferies began covering XERS with “Buy” recommendation on October 21, 2022. Craig Hallum started covering the stock on April 28, 2022. It rated XERS as “a Buy”.
Price Performance Review of XERS
On Friday, Xeris Biopharma Holdings Inc [NASDAQ:XERS] saw its stock fall -5.91% to $1.91. Over the last five days, the stock has lost -6.37%. Xeris Biopharma Holdings Inc shares have fallen nearly -18.72% since the year began. Nevertheless, the stocks have fallen -4.02% over the past one year. While a 52-week high of $3.26 was reached on 02/15/24, a 52-week low of $1.46 was recorded on 04/12/24. SMA at 50 days reached $2.5069, while 200 days put it at $2.2317. A total of 2.05 million shares were traded, compared to the trading of 1.51 million shares in the previous session.
Levels Of Support And Resistance For XERS Stock
The 24-hour chart illustrates a support level at 1.8383, which if violated will result in even more drops to 1.7667. On the upside, there is a resistance level at 2.0133. A further resistance level may holdings at 2.1167. The Relative Strength Index (RSI) on the 14-day chart is 31.85, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0817, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.24%. Stochastics %K at 17.54% indicates the stock is a buying.
The most recent change occurred on November 17, 2021 when SVB Leerink began covering the stock and recommended ‘”an Outperform”‘ rating along with a $6 price target.
